Long-term viral suppression ( hepatitis B virus DNA < @ copies/ml ) was maintained at week @ in @ % and @ % of patients receiving either emtricitabine/tenofovir combination or tenofovir monotherapy , respectively ( non-completer equal to failure analysis ) .